Table of Contents
The cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of this, major pharmaceutical marketers continue to outsource stages of development, and over the years Kalorama Information has observed this process. In past editions of our outsourcing market studies, we found that outsourcing moved from "should" to "must." for manufacturers. This trend has only continued in the past two years.
Contract Research Organizations (CROs) and other entities can expect growing demand for their services. The demand for new drugs remains unabated, but the cost and need to bring those drugs to market is ever-increasing and intensifying. A key cost driver is the large number of failures during the expensive clinical trial phases. Driven by pressures to reduce costs, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry.
Kalorama Information's Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues.
As part of its comprehensive coverage of this market, this report contains:
Find all the market research you need - instantly, in one place.
Talk to Louis
+1 718 618 4302
6 Dimensional Assessment of Lab on a Chip Innovation Landscape A growing trend towards miniaturizing laboratory practices has been a major driving force behind the steady increase of innovations in the ...
This Kalorama Information report defines markets and identifies trends for proteomics applications, both in their research use and in IVD. Proteomics is the study of proteins, including the study of the ...
This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1686 biological ...
Reportlinker.com © Copyright 2014. All rights reserved.